Literature DB >> 11003803

The anti-reflux barrier and mechanisms of gastro-oesophageal reflux.

R H Holloway1.   

Abstract

The lower oesophageal sphincter (LOS) is the major component of the anti-reflux barrier. The majority of reflux episodes occur because of intermittent brief complete lower oesophageal sphincter relaxations, transient LOS relaxations, rather than from chronic absence of LOS pressure. Recent advances in the understanding of the neural mechanisms and the receptors involved in the triggering of transient LOS relaxations have provided new insights into their control and offer the potential for the development of pharmacological therapy of reflux based on control of these events. Extrinsic support by the crural diaphragm is also important and loss of this support through development of hiatus hernia significantly compromises LOS function. This chapter reviews the components of the anti-reflux barrier, the patterns and mechanisms of LOS dysfunction underlying reflux episodes, and the interplay between sphincteric and non-sphincteric factors.

Entities:  

Mesh:

Year:  2000        PMID: 11003803     DOI: 10.1053/bega.2000.0118

Source DB:  PubMed          Journal:  Baillieres Best Pract Res Clin Gastroenterol


  16 in total

Review 1.  Pathophysiological mechanisms of gastroesophageal reflux disease in children.

Authors:  G P Davidson; T I Omari
Journal:  Curr Gastroenterol Rep       Date:  2001-06

2.  Long-term experience of treating 185 patients with gastroesophageal reflux disease (GERD) by anti-reflux surgery respecting the functional-morphological restoration of the esophagus.

Authors:  R Horstmann; C Classen; S Röttgermann; M Langer; D Palmes
Journal:  Langenbecks Arch Surg       Date:  2005-11-18       Impact factor: 3.445

Review 3.  Optimizing the Use of Medications and Other Therapies in Infant Gastroesophageal Reflux.

Authors:  Steven L Ciciora; Frederick W Woodley
Journal:  Paediatr Drugs       Date:  2018-12       Impact factor: 3.022

4.  Endocinch therapy for gastro-oesophageal reflux disease: a one year prospective follow up.

Authors:  Z Mahmood; B P McMahon; Q Arfin; P J Byrne; J V Reynolds; E M Murphy; D G Weir
Journal:  Gut       Date:  2003-01       Impact factor: 23.059

5.  Mechanisms of gastro-oesophageal reflux in preterm and term infants with reflux disease.

Authors:  T I Omari; C P Barnett; M A Benninga; R Lontis; L Goodchild; R R Haslam; J Dent; G P Davidson
Journal:  Gut       Date:  2002-10       Impact factor: 23.059

6.  The size of the esophageal hiatus in gastroesophageal reflux pathophysiology: outcome of intraoperative measurements.

Authors:  Hasan Fevzi Batirel; Oya Uygur-Bayramicli; Adnan Giral; Bülent Ekici; Nural Bekiroglu; Bedrettin Yildizeli; Mustafa Yüksel
Journal:  J Gastrointest Surg       Date:  2009-09-25       Impact factor: 3.452

7.  The role of GABA(A) receptors in the control of transient lower oesophageal sphincter relaxations in the dog.

Authors:  H Beaumont; A-C Jönsson-Rylander; K Carlsson; S Pierrou; M Ahlefelt; L Brändén; J Jensen; G E Boeckxstaens; A Lehmann
Journal:  Br J Pharmacol       Date:  2008-01-21       Impact factor: 8.739

Review 8.  Progress with novel pharmacological strategies for gastro-oesophageal reflux disease.

Authors:  Marcello Tonini; Roberto De Giorgio; Fabrizio De Ponti
Journal:  Drugs       Date:  2004       Impact factor: 9.546

9.  Delivery of radiofrequency energy to the lower oesophageal sphincter and gastric cardia inhibits transient lower oesophageal sphincter relaxations and gastro-oesophageal reflux in patients with reflux disease.

Authors:  W C E Tam; M N Schoeman; Q Zhang; J Dent; R Rigda; D Utley; R H Holloway
Journal:  Gut       Date:  2003-04       Impact factor: 23.059

10.  Effect of delta9-tetrahydrocannabinol, a cannabinoid receptor agonist, on the triggering of transient lower oesophageal sphincter relaxations in dogs and humans.

Authors:  H Beaumont; J Jensen; A Carlsson; M Ruth; A Lehmann; Ge Boeckxstaens
Journal:  Br J Pharmacol       Date:  2008-12-06       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.